Contents

Ros1 RearrangementEdit

Ros1 rearrangement refers to chromosomal rearrangements that fuse the ROS1 gene with various partner genes, producing constitutively active tyrosine kinase signaling that can drive cancer development. First recognized as a clinically actionable driver in a subset of cancers, these rearrangements have since become one of the best-understood targets in precision oncology. The fusion proteins typically retain the kinase domain of ROS1, but acquire dimerization and dysregulated expression from upstream fusion partners, leading to continuous signaling through pathways such as MAPK, PI3K/AKT, and JAK/STAT.

ROS1 is a receptor tyrosine kinase in the same family as the insulin receptor, normally involved in cellular growth and differentiation. In cancer, however, ROS1 becomes linked to fusion partners that contribute strong dimerization domains, enabling ligand-independent activation. The most common fusion partner in non-small cell lung cancer (NSCLC) is CD74, but many others exist, including SLC34A2, EZR, GOPC, SDC4, and CCDC6. The variety of fusion partners means that Ros1 rearrangements can occur across a spectrum of tumor types, though they are most consequential in thoracic malignancies where they define a distinct molecular subset of NSCLC. For more on the gene itself, see ROS1.

Genetic basis and biology

  • Fusion mechanism: In Ros1 rearrangement, the ROS1 kinase domain is fused to the regulatory or dimerization regions of a partner gene. The resulting fusion protein is typically constitutively active, promoting unchecked cell proliferation and survival.
  • Common fusion partners: CD74-ROS1 is the archetype in NSCLC, but other partners include SLC34A2-ROS1, EZR-ROS1, GOPC-ROS1, SDC4-ROS1, and CCDC6-ROS1. Each partner can influence expression level and subcellular localization of the fusion protein.
  • Oncogenic signaling: The activated ROS1 kinase signals through multiple downstream pathways, notably MAPK/ERK, PI3K/AKT, and JAK/STAT, fostering tumor growth and survival.
  • Cancer spectrum: While NSCLC is the most clinically significant setting for Ros1 rearrangement, fusions have been identified in cholangiocarcinoma, glioblastoma, papillary thyroid cancer, inflammatory myofibroblastic tumors, and other solid tumors. For a broader view of fusion-driven cancers, see gene fusion.

Epidemiology and clinical features

  • Prevalence in NSCLC: Ros1 rearrangements occur in a minority of NSCLC, generally around 1–2% of cases, with higher detection in certain histologic subtypes and patient populations.
  • Patient characteristics: In NSCLC, Ros1 rearrangements are more often observed in younger patients and in individuals with little or no tobacco exposure, and they typically present as adenocarcinoma.
  • Prognosis with targeted therapy: The identification of Ros1 rearrangements has transformed management by enabling targeted inhibition of the ROS1 kinase, which can lead to substantial tumor responses and prolonged progression-free survival compared with conventional chemotherapy in appropriately selected patients.

Detection and diagnostics

  • Fluorescence in situ hybridization (FISH): A traditional method that detects rearrangements in the ROS1 locus using break-apart probes. FISH remains a widely used diagnostic standard in many settings.
  • Immunohistochemistry (IHC): IHC can serve as a screening tool to identify tumors likely to harbor Ros1 rearrangements, with positive cases typically confirmed by a molecular assay.
  • Next-generation sequencing (NGS): RNA-based or DNA-based NGS panels can identify the specific fusion partner and breakpoint, offering a comprehensive molecular profile that informs treatment options and potential resistance mechanisms.
  • Other methods: Reverse transcription polymerase chain reaction (RT-PCR) can detect known fusion transcripts, though its utility is limited by the need to know the exact fusion variant ahead of time.
  • Practical approach: In many centers, a tiered strategy begins with IHC screening, followed by confirmatory FISH or NGS to define the fusion partner and guide therapy. See fluorescence in situ hybridization and next-generation sequencing for broader context.

Treatment and clinical management

  • Crizotinib: The first ROS1-targeted therapy approved for Ros1-rearranged NSCLC. It inhibits ROS1 kinase activity and can yield high response rates and meaningful disease control, including intracranial activity in some patients.
  • Entrectinib: A CNS-penetrant inhibitor targeting ROS1 (as well as NTRK fusions and others) with demonstrated efficacy in Ros1-rearranged NSCLC and a favorable CNS activity profile.
  • Lorlatinib and other next-generation inhibitors: Lorlatinib, initially developed for ALK-repositive disease, also shows activity in ROS1-rearranged tumors, including cases with brain involvement, and is used in subsequent-line settings or when resistance to first-line ROS1 inhibitors emerges.
  • Resistance and sequencing: Tumors may develop resistance through secondary ROS1 mutations (such as G2032R) or through activation of alternative signaling pathways. In some situations, switching to a different ROS1 inhibitor or integrating systemic therapy with local treatments for oligoprogression can be considered.
  • CNS considerations: Brain metastases are a concern in Ros1-rearranged NSCLC, and CNS-penetrant inhibitors improve outcomes for patients with intracranial disease. See brain metastasis and crizotinib for related treatment discussions.
  • Other cancers: Targeted ROS1 inhibition is being explored in other Ros1-rearranged tumors, with ongoing clinical trials and real-world data informing broader use. For broader context on targeted therapies in cancer, see targeted therapy.

Controversies and debates (scientific and clinical context)

  • Testing strategies and cost: There is ongoing debate about the most cost-effective and logistically feasible approach to universal Ros1 testing across NSCLC subtypes, balancing the benefits of identifying eligible patients against the costs and turnaround times of comprehensive molecular profiling. See molecular testing.
  • Optimal first-line therapy: Although crizotinib and entrectinib are effective, questions remain about which agent should be preferred as first-line therapy in various clinical scenarios, particularly regarding CNS control and long-term resistance patterns.
  • Access and affordability: Availability of ROS1 inhibitors can vary by region and healthcare system, raising discussions about patient access, insurance coverage, and equitable care. See healthcare access for related topics.
  • Resistance management: As with other targeted therapies, resistance mechanisms limit durability of response. The best strategies for monitoring, early detection of resistance, and sequencing of therapies are active areas of research and debate.

See also